Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H31F3N8O2 |
| Molecular Weight | 568.5933 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCN(C)C1=NC(OCC(F)(F)F)=C(NC2=NC=CC(=N2)C3=CN(C)C4=C3C=CC=C4)C=C1NC(=O)C=C
InChI
InChIKey=GHKOONMJXNWOIW-UHFFFAOYSA-N
InChI=1S/C28H31F3N8O2/c1-6-24(40)33-21-15-22(26(41-17-28(29,30)31)36-25(21)38(4)14-13-37(2)3)35-27-32-12-11-20(34-27)19-16-39(5)23-10-8-7-9-18(19)23/h6-12,15-16H,1,13-14,17H2,2-5H3,(H,33,40)(H,32,34,35)
| Molecular Formula | C28H31F3N8O2 |
| Molecular Weight | 568.5933 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:02:13 GMT 2023
by
admin
on
Sat Dec 16 15:02:13 GMT 2023
|
| Record UNII |
A49A7A5YN4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
118861389
Created by
admin on Sat Dec 16 15:02:14 GMT 2023 , Edited by admin on Sat Dec 16 15:02:14 GMT 2023
|
PRIMARY | |||
|
A49A7A5YN4
Created by
admin on Sat Dec 16 15:02:14 GMT 2023 , Edited by admin on Sat Dec 16 15:02:14 GMT 2023
|
PRIMARY | |||
|
300000039589
Created by
admin on Sat Dec 16 15:02:14 GMT 2023 , Edited by admin on Sat Dec 16 15:02:14 GMT 2023
|
PRIMARY | |||
|
1869057-83-9
Created by
admin on Sat Dec 16 15:02:14 GMT 2023 , Edited by admin on Sat Dec 16 15:02:14 GMT 2023
|
PRIMARY | |||
|
C180535
Created by
admin on Sat Dec 16 15:02:14 GMT 2023 , Edited by admin on Sat Dec 16 15:02:14 GMT 2023
|
PRIMARY | |||
|
12503
Created by
admin on Sat Dec 16 15:02:14 GMT 2023 , Edited by admin on Sat Dec 16 15:02:14 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ≈ 1 nmol/L, which is lower than its IC50 against wild-type EGFR.
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ≈ 1 nmol/L, which is lower than its IC50 against wild-type EGFR.
IC50
|
||
|
TARGET -> INHIBITOR |
Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ≈ 1 nmol/L, which is lower than its IC50 against wild-type EGFR.
IC50
|
||
|
METABOLIC ENZYME -> INDUCER |
Similar to rifampin in its potency to induce CYP3A4
MAJOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| BRAIN/PLASMA RATIO | PHARMACOKINETIC |
|
||||
| Biological Half-life | PHARMACOKINETIC |
|